Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.

Monach PA, Warner RL, Tomasson G, Specks U, Stone JH, Ding L, Fervenza FC, Fessler BJ, Hoffman GS, Iklé D, Kallenberg CG, Krischer J, Langford CA, Mueller M, Seo P, St Clair EW, Spiera R, Tchao N, Ytterberg SR, Johnson KJ, Merkel PA.

Ann Rheum Dis. 2013 Aug;72(8):1342-50. doi: 10.1136/annrheumdis-2012-201981. Epub 2012 Sep 12.

2.

Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.

Monach PA, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Ding L, Fervenza FC, Fessler BJ, Hoffman GS, Ikle D, Kallenberg CG, Langford CA, Mueller M, Seo P, St Clair EW, Spiera R, Tchao N, Ytterberg SR, Gu YZ, Snyder RD, Merkel PA.

Arthritis Rheum. 2011 Dec;63(12):3988-97. doi: 10.1002/art.30615.

3.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.

Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC; Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group.

J Am Soc Nephrol. 2015 Apr;26(4):976-85. doi: 10.1681/ASN.2014010046. Epub 2014 Nov 7.

4.

Platelet counts as a biomarker in ANCA-associated vasculitis.

Willeke P, Kümpers P, Schlüter B, Limani A, Becker H, Schotte H.

Scand J Rheumatol. 2015;44(4):302-8. doi: 10.3109/03009742.2015.1006247. Epub 2015 Mar 6.

PMID:
25744854
5.

Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.

Timlin H, Lee SM, Manno RL, Seo P, Geetha D.

Semin Arthritis Rheum. 2015 Aug;45(1):67-9. doi: 10.1016/j.semarthrit.2015.02.005. Epub 2015 Feb 20.

6.
7.

Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.

Wendt M, Gunnarsson I, Bratt J, Bruchfeld A.

Scand J Rheumatol. 2012 Mar;41(2):116-9. doi: 10.3109/03009742.2011.620573. Epub 2011 Nov 28.

PMID:
22118245
8.

Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis.

Monach PA, Kümpers P, Lukasz A, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Carette S, Ding L, Hoffman GS, Iklé D, Kallenberg CG, Khalidi NA, Langford CA, Seo P, St Clair EW, Spiera R, Tchao N, Ytterberg SR, Haubitz M, Merkel PA.

PLoS One. 2012;7(1):e30197. doi: 10.1371/journal.pone.0030197. Epub 2012 Jan 18.

9.

Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Pepper RJ, Draibe JB, Caplin B, Fervenza FC, Hoffman GS, Kallenberg CG, Langford CA, Monach PA, Seo P, Spiera R, William St Clair E, Tchao NK, Stone JH, Specks U, Merkel PA, Salama AD; RAVE-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2017 Jan;69(1):185-193. doi: 10.1002/art.39814.

10.

Induction treatment of ANCA-associated vasculitis with a single dose of rituximab.

Turner-Stokes T, Sandhu E, Pepper RJ, Stolagiewicz NE, Ashley C, Dinneen D, Howie AJ, Salama AD, Burns A, Little MA.

Rheumatology (Oxford). 2014 Aug;53(8):1395-403. doi: 10.1093/rheumatology/ket489. Epub 2014 Mar 7.

PMID:
24609057
11.

Serum decoy receptor 3 levels are associated with the disease activity of MPO-ANCA-associated renal vasculitis.

Maruyama H, Hirayama K, Nagai M, Ebihara I, Shimohata H, Kobayashi M.

Clin Rheumatol. 2016 Oct;35(10):2469-76. doi: 10.1007/s10067-016-3321-y. Epub 2016 Jun 1.

PMID:
27251675
12.

[Kidney injury molecules (KIM-1, MCP-1) and type IV collagen in the assessment of activity of antineutrophil cytoplasmic antibody-associated glomerulonephritis].

Bulanov NM, Serova AG, Kuznetsova EI, Bulanova ML, Novikov PI, Kozlovskaya LV, Moiseev SV.

Ter Arkh. 2017;89(6):48-55. doi: 10.17116/terarkh201789648-55. Russian.

PMID:
28745689
14.

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Iklé D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheum. 2013 Sep;65(9):2441-9. doi: 10.1002/art.38044.

15.

urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Lieberthal JG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, Langford CA, Maksimowicz-McKinnon K, Seo P, Specks U, Ytterberg SR, Merkel PA, Monach PA; Vasculitis Clinical Research Consortium.

J Rheumatol. 2013 May;40(5):674-83. doi: 10.3899/jrheum.120879. Epub 2013 Apr 1.

16.

Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.

Md Yusof MY, Vital EM, Das S, Dass S, Arumugakani G, Savic S, Rawstron AC, Emery P.

Ann Rheum Dis. 2015 Sep;74(9):1734-8. doi: 10.1136/annrheumdis-2014-206496. Epub 2015 Apr 8.

PMID:
25854586
17.

Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab.

Berti A, Cavalli G, Campochiaro C, Guglielmi B, Baldissera E, Cappio S, Sabbadini MG, Doglioni C, Dagna L.

Semin Arthritis Rheum. 2015 Aug;45(1):48-54. doi: 10.1016/j.semarthrit.2015.02.002. Epub 2015 Feb 20.

PMID:
25841802
18.

Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment.

Nasrallah M, Pouliot Y, Hartmann B, Dunn P, Thomson E, Wiser J, Butte AJ.

Arthritis Res Ther. 2015 Sep 21;17:262. doi: 10.1186/s13075-015-0778-z.

19.

Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?

Tesar V.

Nephrol Dial Transplant. 2015 Jul;30(7):1088-90. doi: 10.1093/ndt/gfv215. Epub 2015 May 21.

PMID:
25999373
20.

Increased levels of neutrophil extracellular trap remnants in the circulation of patients with small vessel vasculitis, but an inverse correlation to anti-neutrophil cytoplasmic antibodies during remission.

Söderberg D, Kurz T, Motamedi A, Hellmark T, Eriksson P, Segelmark M.

Rheumatology (Oxford). 2015 Nov;54(11):2085-94. doi: 10.1093/rheumatology/kev217. Epub 2015 Jul 12.

Supplemental Content

Support Center